|
|
Volumn 58, Issue 2, 2001, Pages 146-150
|
|
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
a,l
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BICALUTAMIDE;
PLACEBO;
PROSTATE SPECIFIC ANTIGEN;
ADULT;
ADVANCED CANCER;
AGED;
ARTICLE;
CANCER ADJUVANT THERAPY;
CANCER GROWTH;
CANCER MORTALITY;
CANCER RISK;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG ACTIVITY;
DRUG EFFECT;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG TOLERABILITY;
FOLLOW UP;
GYNECOMASTIA;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MASTALGIA;
MULTICENTER STUDY;
PATIENT MONITORING;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
PROSTATE CARCINOMA;
PROSTATECTOMY;
RANDOMIZED CONTROLLED TRIAL;
STATISTICS;
TREATMENT OUTCOME;
ADULT;
AGED;
AGED, 80 AND OVER;
ANDROGEN ANTAGONISTS;
ANILIDES;
CONFIDENCE INTERVALS;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
DOUBLE-BLIND METHOD;
FOLLOW-UP STUDIES;
GYNECOMASTIA;
HUMANS;
MALE;
MIDDLE AGED;
PAIN;
PROSPECTIVE STUDIES;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
SURVIVAL RATE;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 0034909945
PISSN: 00904295
EISSN: None
Source Type: Journal
DOI: 10.1016/S0090-4295(01)01213-4 Document Type: Article |
|
Times cited : (80)
|
|
References (14)
|
